Every year, more than 3,000 scientific abstracts are accepted for oral and poster presentation at the Society's annual meeting.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to biomedical research
Hear top experts in hematologic malignancies discuss the latest developments in clinical care.
Thoughtful commentaries on several of the most meaningful hematologic breakthroughs of 2014, written by editors of The Hematologist and selected guest experts.
Obtain CME credit and a certificate of attendance for the 56th ASH Annual Meeting by April 17, 2015.
Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to medical research.
Search a database of practicing hematologists in your area.
Help move hematology forward by supporting research, career development, and quality care and education programs.
Become part of a global network of more than 16,000 hematologists working to conquer blood diseases.
A committee of lymphoma experts today unveiled a strategic roadmap identifying key priority areas in both infrastructure and research that will be critical for advancing treatments for people with lymphoma.
Today the House of
Representatives passed legislation that would repeal the Sustainable Growth
Rate, a flawed formula mandating scheduled reductions in Medicare
physician payments, and replace it with a 0.5 percent annual physician pay
increase for the next five years.
New research reports that when compared to healthy pregnant
women, pregnant women with a severe form of sickle cell disease are six
times more likely to die during or following pregnancy and have an increased
risk for stillbirth, high blood pressure, and preterm delivery.
Jacqueline C. Barrientos, MD, of Hofstra North Shore–Long Island Jewish (LIJ) School of Medicine/The Feinstein Institute of Medical Research and Johnnie J. Orozco, MD, PhD, of Fred Hutchinson Cancer Research Center have been selected to participate in the 2015 American Society of Hematology-Harold Amos Medical Faculty Development Program (ASH-AMFDP). Dr. Barrientos will study Richter’s Syndrome, and Dr. Orozco will study the use of alpha radioimmunotherapy to improve haploidentical bone marrow transplantation.
On March 19, the House of Representatives introduced a bill that would permanently address the SGR issue. This bill largely follows the
policy of the bill that was introduced by the committees of jurisdiction during
the last Congress. That bill, which ASH
supported, eliminated the SGR update formula in favor of a new payment schedule. Follow the link above to read more about the bill.
On February 12, 2015, the Center for Medicare and Medicaid Innovation (CMMI) revealed the opportunity for practices to participate in a payment model dedicated the care of patients with cancer. Although there will be additional details to finalize, CMMI would like practices to express interest in participating in the model by April 23, 2015, even though it will not begin paying with this method until 2016. Click on the headline to read more.
On January 30, ASH submitted comments on the Food and Drug Administration's (FDA)
on Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs). The Guidance Document proposes that FDA assert its regulatory authority and increase oversight of LDTs. Click on the link above to read more about ASH's comments.
On January 28, The American Society of Hematology (ASH) submitted
on the National Institutes of Health's (NIH) Draft Policy to promote the use of a single Institutional Review Board (IRB) of record for domestic sites of multi-site clinical studies funded by NIH. The draft NIH policy proposes that all NIH-funded, multi-site studies carried out in the United States, whether supported through grants, contracts, or the NIH intramural program, should use a single IRB. Read more to learn about ASH's stance on the policy.
Dr. Levine and Dr. Gilliland discuss developments that have come about in the past 10 years regarding JAK2 V617F after Dr. Dameshek's study of the classification of different MPNs in 2005.
ASH's Visitor Training Program grant helped bring Dr. Tamunomieibi Wakama to train in diagnostic hematopathology at Roswell Park Cancer Institute (RPCI).
Dr. Verstovsek discusses the benefits of treatment with JAK Inhibitors through the study of three clinical trials.
New Drugs to Match My New Genes? A Look Back at the 56th ASH Annual Meeting
For us hematologists, the first full weekend in December is typically blacked out in our calendars. During this sacred time, ASH hosts its annual meeting for anyone interested in the basic science, clinical
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology